[ad_1]
The Dental and Pharmaceutical Benefit Office (TLV) has decided to extend the Xeljanz (tofacitinib) subsidy to the indications for psoriatic arthritis and ulcerative colitis.1. This decision means that even these patient groups now have access to a new treatment option in tablet form. The decision applies from October 26th. Xeljanz is included in the high cost protection of rheumatoid arthritis indication since April 2017.
Xeljanz (tofacitinib) is the first and only Januskinase Inhibitor (JAK) approved for three indications in adults: moderate to severe active rheumatoid arthritis (March 2017), active psoriatic arthritis (June 2018) and active progressive colitis moderate to severe (July 2018). ).
TLV's decision now means that Xeljanz is included in the high-cost protection for the three indications.
TLV writes in the grant decision that the cost of Xeljanz treatment for ulcerative colitis is lower than the cost of the comparison options. TLV also believes that the cost of treating psoriatic arthritis is reasonable.
About psoriatic arthritis
Psoriatic arthritis is a chronic autoimmune inflammatory disease that can manifest itself in both large and small joints, including the back, tendons, ligaments and skin.2 Psoriatic arthritis can cause various symptoms such as joint pain and stiffness, swelling of the toes and / or fingers, and limitation of mobility. 2,3,4
About ulcerative colitis
Ulcerative colitis is a chronic and often disabling inflammatory bowel disease affecting approximately 2.1 million people in Europe.5,6,7 Symptoms of ulcerative colitis may include chronic diarrhea with blood and mucus, stomach pain and cramps, as well as weight loss.8.9 Ulcerative colitis can have major effects on work, family and social activities.9
About Xeljanz
Xeljanz contains the active substance tofacitinib, a JAK inhibitor. Inhibition of JAK causes a decrease in inflammation.
Xeljanz (tofacitinib) is the first and only JAK inhibitor approved in three indications in adults: moderate to severe active rheumatoid arthritis, active psoriatic arthritis, and moderate to severe active ulcerative colitis.
The recommended dose for rheumatoid arthritis and psoriasis is 5 mg twice daily, while the recommended dose for ulcerative colitis is 10 mg twice daily for 8 weeks, followed by 5 mg twice daily day.
Full information on Xeljanz's prescription is available on www.fass.se
references
(1) https://www.tlv.se/download/18.13634819166e2df8686999985/1541428546774/bes181025_xeljanz.pdf
(2) Strauss, EJ. Orthopedic manifestations and management of psoriatic arthritis. American Journal of Orthopedics. 2008: 37 (3): 138-47.
(3) National Institute of Arthritis and Diseases of the Musculoskeletal and Skin (NIAMS). Overview of psoriatic arthritis. https://www.niams.nih.gov/health-topics/psoriatic-arthritis. Accessed October 29, 2018.
(4) Foundation of arthritis. Symptoms of psoriatic arthritis. http://www.arthritis.org/about-arthritis/types/psoriatic-arthritis/symptoms.php. Accessed October 29, 2018.
(5) Crohn's and Colitis Foundation. What is ulcerative colitis? Available at:
http://www.crohnscolitisfoundation.org/what-are-crohns-and-colitis/what-is-ulcerative-colitis. Accessed October 29, 2018.
(6) Burisch J, et al. The burden of inflammatory bowel disease in Europe. Crohn's and Colitis Journal. 2013. 7 (4): 322-337.
(7) Choice of the NHS. Ulcerative colitis: living with. Available at the following address: https://www.nhs.uk/conditions/ulcerative-colitis/living-with/. Accessed October 29, 2018.
(8) Hanauer SB. Inflammatory disease of the intestine. N Engl J Med. 1996; 334 (13): 841-8.
(9) Irvine EJ. Quality of life of patients with ulcerative colitis: past, present and future. Inflammatory diseases of the intestine. 2008: 14 (4): 554-563.
Source link
